Trial Profile
A Double-blind, Randomised, Placebo-controlled Trial Evaluating the Effect of BI 655064 Administered as Sub-cutaneous Injections, on Renal Response After One Year of Treatment, in Patients With Active Lupus Nephritis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 May 2023
Price :
$35
*
At a glance
- Drugs BI 655064 (Primary)
- Indications Lupus nephritis
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim; Boehringer Ingelheim Pharma KG
- 16 May 2023 Results of post hoc analysis of Clinical and biomarker responses to BI 655064, published in the Arthritis and Rheumatology
- 05 Jun 2021 Primary endpoint (Proportion of patients with complete renal response) has not been met, according to Results presented at the 22nd Annual Congress of the European League Against Rheumatism.
- 05 Jun 2021 Results assessing efficacy and safety over 52 weeks of three doses of subcutaneous BI 655064 compared with placebo, presented at the 22nd Annual Congress of the European League Against Rheumatism.